Answers are grounded in this paper and cite their sources.
Transforming growth factor-β (TGFβ) is a pleiotropic cytokine that signals via ubiquitously expressed TGFβ type I and type II receptors, TGFBR1 and TGFBR2. TGFβ plays crucial roles in maintaining tissue homeostasis, and dysregulation underlies a wide range of human diseases. In immune homeostasis, TGFβ is primarily immunosuppressive. Excessive TGFβ signaling can contribute to cancer cell immune evasion. Current TGFβ targeting agents are non-cell-selective. Cell-selective TGFβ modulators may provide important tools to determine which TGFβ target cells drive a particular pathophysiological or therapeutic response. Bispecific antibodies (BsAbs) comprising a TGFBR2 specific nanobody and a CD4-, CD8α-, or CD8β specific antibody targeting moiety were designed and functionally characterized to selectively inhibit TGFβ signaling in (engineered) cell (mixtures) and primary CD4+ and CD8+ T cells using cell proliferation and differentiation assays, immunoblotting, transcriptional fluorescent response assays using Incucyte Life Cell Imaging, fluorescence-activated cell sorting, and/or receptor binding experiments with radiolabeled TGFβ. We generated BsAbs by fusing a TGFBR2 specific nanobody to a CD4-, CD8α-, or CD8β-specific antibody to inhibit TGFβ signaling in CD4+ or CD8+ T cells selectively. The TGFBR2 nanobody alone does not antagonize TGFβ signaling, and CD4-, CD8α-, or CD8β-antibodies bind with high affinity to their respective receptors but do not affect immune cell function. Mechanistically, we show that TGFBR2xCD4 or TGFBR2xCD8 BsAbs selectively block TGFβ binding to TGFBR2 in CD4- and CD8-expressing cells, respectively. TGFBR2xCD4 BsAb inhibited TGFβ-induced differentiation of CD4+ T cells into regulatory T cells. TGFBR2xCD8 BsAb antagonized TGFβ-induced inhibition of naïve CD8+ T cell proliferation. We generated and characterized BsAbs that selectively inhibit TGFβ signaling in CD4+, CD8α+, or CD8β+ cells. These BsAbs enable specific assessment of the contribution of CD4+ or CD8+ T cells to TGFβ-induced multifunctional responses. The modular design of our BsAbs allows cell biologists or drug developers, based on their needs, to develop tools to precisely direct TGFβ inhibition to selective cell types, while avoiding the off-target systemic effects of current non-cell-selective inhibitors.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: